Keros Therapeutics (KROS) EBIT (2019 - 2025)
Keros Therapeutics (KROS) reported EBIT of -$29.3 million for Q4 2025, up 45.04% on a YoY basis from -$20.2 million in Q4 2024, and down 90.26% quarter-over-quarter from -$15.4 million in Q3 2025.
Keros Therapeutics (KROS) EBIT (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported EBIT for 7 years, with the latest figure at -$29.3 million in Q4 2025.
- For the quarter ending Q4 2025, EBIT rose 45.04% year-over-year to -$29.3 million; the trailing twelve-month figure through Dec 2025 stood at $67.6 million (up 132.05% YoY), and the FY2025 full-year result was $67.6 million, up 132.05% from the prior year.
- EBIT for Q4 2025 stood at -$29.3 million, down from -$15.4 million in the prior quarter.
- The five-year high for EBIT was $152.0 million in Q1 2025, with the low at -$58.7 million in Q3 2024.
- Historically, EBIT has averaged -$24.2 million across 5 years, with a median of -$31.3 million in 2022.
- Annual changes were most pronounced in 2022 — EBIT sank 556.8% — and 2025, when it surged 413.59%.
- Keros Therapeutics' EBIT stood at -$4.9 million in 2021, then slumped by 556.8% to -$32.0 million in 2022, then slumped by 45.35% to -$46.5 million in 2023, then retreated by 14.64% to -$53.3 million in 2024, then soared by 45.04% to -$29.3 million in 2025.
- The last three EBIT figures came in at -$29.3 million (Q4 2025), -$15.4 million (Q3 2025), and -$39.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | -29.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -29.27 Mn |
| Sep 30, 2025 | -15.38 Mn |
| Jun 30, 2025 | -39.82 Mn |
| Mar 31, 2025 | 152.04 Mn |
| Dec 31, 2024 | -53.25 Mn |
| Sep 30, 2024 | -58.66 Mn |
| Jun 30, 2024 | -50.44 Mn |
| Mar 31, 2024 | -48.48 Mn |
| Dec 31, 2023 | -46.46 Mn |
| Sep 30, 2023 | -43.28 Mn |
| Jun 30, 2023 | -41.34 Mn |
| Mar 31, 2023 | -38.87 Mn |
| Dec 31, 2022 | -31.96 Mn |
| Sep 30, 2022 | -27.98 Mn |
| Jun 30, 2022 | -30.73 Mn |
| Mar 31, 2022 | -24.13 Mn |
| Dec 31, 2021 | -4.87 Mn |
| Sep 30, 2021 | -20.20 Mn |
| Jun 30, 2021 | -15.54 Mn |
| Mar 31, 2021 | -15.77 Mn |